Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis (CSTCMDTCHSPN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02878018|
Recruitment Status : Enrolling by invitation
First Posted : August 25, 2016
Last Update Posted : November 17, 2017
|Condition or disease||Intervention/treatment|
|Henoch-Schonlein Purpura Nephritis||Drug: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula Drug: angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|
Background: Henoch-Schönlein purpura nephritis involves the renal impairment of Henoch-Schönlein purpura and can easily relapse into life-threatening late nephropathy in severe cases. Although there is a lack of validated evidence for its effectiveness, traditional Chinese medicine is the most commonly used method in China to treat Henoch-Schönlein purpura nephritis. We report the protocol of a prospective cohort trial using traditional Chinese medicine to investigate the effectiveness, safety and advantages for children with Henoch-Schönlein purpura nephritis.
Methods/Design: A large, prospective, multicenter cohort study is being conducted in three institutions. Eligible Henoch-Schönlein purpura nephritis children will be classified as the experimental group (n=300) and the control group (n=300) based on the interventions they receive. Patients taking Chinese herbal formula will be in the experimental group, and those taking Western medicine will be in the control group. The entire study will last 60 weeks, including a 12-week observation period and a followup at 12 months. Seven visits will be scheduled for each participant with visits in week 0, week 2, week 4, week 6, week 8, week 10 and week 12. The primary outcomes include the remission rate and the recurrence rate. The secondary outcomes include the urine erythrocyte effectiveness, the urine protein effectiveness, the hormone usage rate, the immunosuppressant usage rate, and the incidence rate of renal failure. Safety outcomes and any adverse reactions will be recorded during the study.
Discussion: This study will determine whether the Chinese herbal formula is helpful for treating Henoch-Schönlein purpura nephritis in children. The findings will provide a basis for further confirmatory studies.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||600 participants|
|Target Follow-Up Duration:||12 Months|
|Official Title:||Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||May 2020|
Participants with HSPN of the Heat-Toxin type will take the Qi-Ji Shen-Kang formula. HSPN patients of the Wet-Heat type will take the Zhu-Bai formula. Those of Qi-Deficiency with Blood-Stasis type will take the Yu-Shen formula.
Drug: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula
Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
WM conventional intervention
The WM conventional intervention, recommended by the Chinese Medical Association's (CMA) Scientific Statement, includes angiotensin-converting enzyme (ACE) inhibitor, adrenergic receptor binder (ARB), adrenal cortical hormone, Tripterygium wilfordii polyglycosidium and an immunosuppressant.
Drug: angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant
prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
- Urine protein [ Time Frame: 2 weeks ]
- Recovery:Urine protein(-).
- Marked effect:Urine protein reduces by 2'+'.
- Effective：Urine protein reduces by 1'+'.
- Ineffective：Urine protein has no changes.
- 24-hour urinary protein excretion [ Time Frame: 2 weeks ]
- Recovery:24-hour urinary protein excretion is normal.
- Marked effect:24-hour urinary protein excretion reduction is larger than 50%.
- Effective：24-hour urinary protein excretion reduction is smaller than 50%.
- Ineffective：24-hour urinary protein excretion has no changes.
- Urine erythrocyte [ Time Frame: 2 weeks ]
- Recovery:Urine erythrocyte is normal.
- Marked effect:Urine erythrocyte reduction is larger than 50%.
- Effective:Urine erythrocyte reduction is smaller than 50%.
- Ineffective；Urine erythrocyte has no changes.
- Creatinine clearance rate and Serum creatinine [ Time Frame: 1 year ]
Diagnostic criteria of chronic renal failure:
- Creatinine clearance rate<80ml/min;
- Serum creatinine>133μmol/L;
- The patient who have a history of chronic kidney diseases or systemic diseases involving kidney.
- Number of patients with hormone therapy [ Time Frame: 3 months ]Hormone utilized rate=Number of patients with hormone therapy/The total number of patients
- Number of patients with immunosuppressant therapy [ Time Frame: 3 months ]Immunosuppressant utilized rate=Number of patients with immunosuppressant therapy/The total number of patients
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02878018
|Shenyang, Liaoning, China, 110032|
|Study Chair:||jun zhang, master||Affiliated Hospital of Liaoning University of Traditional Chinese Medicine|
|Study Director:||jing lv, master||Affiliated Hospital of Liaoning University of Traditional Chinese Medicine|
|Principal Investigator:||shaoqing zhang, doctor||Affiliated Hospital of Liaoning University of Traditional Chinese Medicine|
|Principal Investigator:||guanqi yang, doctor||Affiliated Hospital of Liaoning University of Traditional Chinese Medicine|
|Principal Investigator:||shuang pang, doctor||Affiliated Hospital of Liaoning University of Traditional Chinese Medicine|
|Principal Investigator:||binyu wu, master||Shengjing Hospital|
|Principal Investigator:||yaoguo zhang, master||First Hospital of China Medical University|